Kura Oncology reports Q1 2026 ziftomenib revenue of $5.8M with 85 new patient starts and repeat prescription signals in...

Boehringer Ingelheim licenses a preclinical antibody from Immunitas for inflammatory diseases, with milestone payments reaching €407.5 million.

Collegium Acquires AZSTARYS from Corium for $650 million, betting the ADHD treatment is undercommercialized and projecting $60–70 million in...

Lilly's ATTAIN-MAINTAIN trial shows Foundayo maintains weight loss after injectable GLP-1s — a $42B market's access problem just found...

Halozyme Q1 royalties rise 43% to $241M on ENHANZE growth; 2026 guidance maintained as new licensing deals extend royalty...

Sana's UP421 trial shows 14 months of C-peptide production in a patient without immunosuppression, marking significant progress in islet...

SCYNEXIS launches SCY-770 ADPKD program with $72.4M cash runway. Phase 2 trial planned for Q4 2026 with efficacy readout...

Erasca and Merck partner on ERAS-0015 and pembrolizumab to target RAS mutations, with Merck supplying KEYTRUDA at no cost...

MoonLake Clears FDA Pre-BLA Meeting with no remediation items, positioning for September 2026 HS drug submission and mid-2027 approval.

BMS and Hengrui Pharma announce $15.2B strategic deal on oncology and immunology, with exclusive worldwide rights outside mainland China...